Vol 47, No 3 (2013)

open access

Page views 597
Article views/downloads 340
Get Citation

Connect on Social Media

Connect on Social Media

Magnetic resonance spectroscopy and molecular studies in ornithine transcarbamylase deficiency novel mutation c.802A > G in exon 8 (p.Met268Val)

Ewa Jamroz1, Justyna Paprocka1, Maria Sokół2, Ewa Popowska3, Elżbieta Ciara3
DOI: 10.5114/ninp.2013.35488
Neurol Neurochir Pol 2013;47(3):283-289.

Abstract

Abstract

Ornithine transcarbamylase (OTC) deficiency, an X-linked, semidominant disorder, is the most common inherited defect in ureagenesis, resulting in hyperammonaemia type II. The OTC gene, localised on chromosome X, has been mapped to band Xp21.1, proximate to the Duchenne muscular dystrophy (DMD) gene. More than 350 different mutations, including missense, nonsense, splice-site changes, small deletions or insertions and gross deletions, have been described so far. Almost all mutations in consensus splicing sites confer a neonatal phenotype. Most mutations in the OTC gene are ‘private’ and are distributed throughout the gene with a paucity of mutation in the sequence encoding the leader peptide (exon 1 and beginning of exon 2) and in exon 7. They have familial origin or occur de novo. Even with sequencing of the entire reading frame and exon/intron boundaries, only about 80% of the mutations are detected in patients with proven OTC deficiency. The remainder probably occur within the introns or in regulatory domains. The authors present a 4-year-old boy with the unreported missense mutation c.802A>G. The nucleotide transition leads to amino acid substitution Met to Val at codon 268 of the OTC protein.

Article available in PDF format

View PDF Download PDF file



Neurologia i Neurochirurgia Polska